肠脑互动障碍的餐后症状及其作为治疗靶点的潜力
本文提出肠脑互动障碍(含功能性消化不良与肠易激综合征)的餐后症状源于独特病理生理过程:急性肠道感染等打击导致对既往耐受的口服食物抗原失去耐受,微生物群与食物抗原和免疫系统相互作用,激活嗜酸性粒细胞与肥大细胞并释放组胺与细胞因子,进而触发伤害性神经并改变情绪。饮食干预与具抗组胺作用的药物可能通过调节该过程获益,但食物抗原驱动免疫激活并非全部解释。
要点
- 餐后症状可能由食物抗原驱动局部免疫反应所致。
- 低FODMAP饮食、剔除食物抗原等饮食干预可能使部分患者获益。
- 质子泵抑制剂、组胺受体拮抗剂、肥大细胞稳定剂或三环/四环类抗抑郁药作用于上述机制。
核心结论
- 若餐后症状源于食物抗原驱动胃肠道免疫反应这一概念在部分患者中成立,则具有范式转变意义,基于这些治疗靶点选择治疗可能改善患者结局。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 生理或心理打击如急性肠道感染可导致对既往耐受的口服食物抗原失去耐受。
- 微生物群与食物抗原和免疫系统相互作用,引起局部免疫反应,激活嗜酸性粒细胞与肥大细胞并释放组胺和细胞因子等炎症介质。
- 这些介质具有更广泛的全身效应,包括触发伤害性神经和改变情绪。
- 低FODMAP饮食、剔除潜在食物抗原或麸质、IgG食物敏感饮食或水杨酸盐限制可能使部分IBS或FD患者获益。
- 食物抗原驱动肠道免疫激活似乎不太可能是FD和IBS餐后症状的全部解释。
关键数值与推荐
- 饮食干预包括低FODMAP饮食、剔除潜在食物抗原或麸质、IgG食物敏感饮食或水杨酸盐限制可能使部分IBS或FD患者获益。
- 药物包括质子泵抑制剂、组胺受体拮抗剂、肥大细胞稳定剂或具抗组胺作用的三环或四环类抗抑郁药均作用于一个或多个上述机制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 食物抗原驱动肠道免疫激活似乎不太可能是FD和IBS餐后症状的全部解释。
- 在其他患者中,肠道碳水化合物发酵产气改变反射反应、对食物化学物质的不良反应、中枢机制或反安慰剂效应可能占主导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Postprandial, or meal-related, symptoms, such as abdominal pain, early satiation, fullness or bloating, are often reported by patients with disorders of gut-brain interaction, including functional dyspepsia (FD) or irritable bowel syndrome (IBS). We propose that postprandial symptoms arise via a distinct pathophysiological process. A physiological or psychological insult, for example, acute enteric infection, leads to loss of tolerance to a previously tolerated oral food antigen. This enables interaction of both the microbiota and the food antigen itself with the immune system, causing a localised immunological response, with activation of eosinophils and mast cells, and release of inflammatory mediators, including histamine and cytokines. These have more widespread systemic effects, including triggering nociceptive nerves and altering mood. Dietary interventions, including a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols, elimination of potential food antigens or gluten, IgG food sensitivity diets or salicylate restriction may benefit some patients with IBS or FD. This could be because the restriction of these foods or dietary components modulates this pathophysiological process. Similarly, drugs including proton pump inhibitors, histamine-receptor antagonists, mast cell stabilisers or even tricyclic or tetracyclic antidepressants, which have anti-histaminergic actions, all of which are potential treatments for FD and IBS, act on one or more of these mechanisms. It seems unlikely that food antigens driving intestinal immune activation are the entire explanation for postprandial symptoms in FD and IBS. In others, fermentation of intestinal carbohydrates, with gas release altering reflex responses, adverse reactions to food chemicals, central mechanisms or nocebo effects may dominate. However, if the concept that postprandial symptoms arise from food antigens driving an immune response in the gastrointestinal tract in a subset of patients is correct, it is paradigm-shifting, because if the choice of treatment were based on one or more of these therapeutic targets, patient outcomes may be improved.
引用
- Ford AC, Staudacher HM, Talley NJ, et al. Postprandial symptoms in disorders of gut-brain interaction and their potential as a treatment target. Gut. 2024. PMID: 38697774. doi:10.1136/gutjnl-2023-331833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。